navafenterol
- Generic Name
- navafenterol
A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases.
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2018-08-24
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 73
- Registration Number
- NCT03645434
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Male Japanese Subjects
Phase 1
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease - COPD
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-05-18
- Last Posted Date
- 2017-10-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 25
- Registration Number
- NCT03159442
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Subjects
Phase 1
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-06-28
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT02814656
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath